CoChat

The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease

Kjekshus, John, Pedersen, Terje R., Olsson, Anders G., Færgeman, Ole, Pyörälä, Kalevi · 1997 · Journal of Cardiac Failure

The DOI matches its Crossref record; 14 of the 15 references it cites were found in a registry or an index.

Abstract

Background Although treatment of myocardial overload effectively reduces death from progression of heart failure, it is not known whether the retardation of progressive coronary artery disease obtained with lipid lowering treatment will prevent the onset and consequences of heart failure in patients without previous symptoms of heart failure.Methods and results In the Scandinavian Simvastatin Survival Study, 4444 patients with coronary heart disease without evidence of heart failure were randomized to placebo (n = 2223) or simvastatin 20-40 mg (n = 2221) and followed for more than 5 years. Among the patients who received placebo, 228 (10.3%) were diagnosed with heart failure during follow-up evaluation compared with 184 (8.3%) of patients who received simvastatin (P < .015). Mortality was 31.9% in the placebo group and 25.5% in the simvastatin group among patients who developed heart failure. These compare with 9.2 and 6.6%, respectively, among non-heart failure patients. There were 45 hospitalizations because of acute heart failure in the placebo group and 23 in the simvastatin group (NS). Patients who developed heart failure were more likely to have suffered a recurrent myocardial infarction and have a history of diabetes, peripheral artery disease, and hypertension than patients who did not develop congestive heart failure.Conclusion Long-term prevention with simvastatin reduces the occurrence of heart failure in a cohort of patients with coronary heart disease without previous evidence of congestive heart failure.

Overview

Integrity signals

Registry

Crossref · 10.1016/s1071-9164(97)90022-1

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 14 references

Research works printed but not linked: 1

  1. Meredith, 1993, Role of impaired endothelium-dependent vasodilatation in ischemic manifestations of coronary artery disease, Circulation, 87, V56

Cited by

See all 386

Metadata

Authors
Kjekshus, J., Pedersen, T. R., Olsson, A. G., Færgeman, O., & Pyörälä, K.
Affiliations
Linköping University (SE)
Corresponding author
Kjekshus, John
Venue
Journal of Cardiac Failure
Publisher
Elsevier BV
Published
1997-12
Volume
3
Issue
4
Pages
249-254
ISSN
1071-9164 (ISSN-L)
OpenAlex
W2091243061
Cited by
386
References
15
Citations by year
2026: 4 · 2025: 2 · 2024: 2 · 2023: 4 · 2022: 4 · 2021: 5 · 2020: 7 · 2019: 7 · 2018: 3 · 2017: 6 · 2016: 16 · 2015: 10 · 2014: 3 · 2013: 19 · 2012: 8
FWCI
7.66
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Journal of Cardiac Failure (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords
simvastatin, heart failure prevention, coronary artery disease, lipid-lowering therapy, statins, heart failure incidence, mortality, Scandinavian Simvastatin Survival Study, heart failure risk
MeSH terms
Adult, Aged, Anticholesteremic Agents, Coronary Disease, Heart Failure, Humans, Middle Aged, Retrospective Studies, Multicenter Studies as Topic, Survival Analysis, Randomized Controlled Trials as Topic, Disease Progression, Simvastatin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. https://app.cochat.ai/papers/10.1016/s1071-9164(97)90022-1
The paper
Kjekshus, J., Pedersen, T. R., Olsson, A. G., Færgeman, O., & Pyörälä, K. (1997). The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. Journal of Cardiac Failure. https://doi.org/10.1016/s1071-9164(97)90022-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.